Cargando…
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack o...
Autores principales: | Bollani, Lina, Baraldi, Eugenio, Chirico, Gaetano, Dotta, Andrea, Lanari, Marcello, Del Vecchio, Antonello, Manzoni, Paolo, Boldrini, Antonio, Paolillo, Piermichele, Di Fabio, Sandra, Orfeo, Luigi, Stronati, Mauro, Romagnoli, Costantino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681171/ https://www.ncbi.nlm.nih.gov/pubmed/26670908 http://dx.doi.org/10.1186/s13052-015-0203-x |
Ejemplares similares
-
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008) -
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009) -
A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012) -
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age
por: Keary, Ian P., et al.
Publicado: (2023) -
Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)